Proteomika mozkomíšního moku u dětských onkologických pacientů

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Title in English Proteomics of cerebrospinal fluid in pediatric oncology patients
Authors

ZAPLETALOVÁ Danica MÚDRY Peter DANHOFER Pavlína BARRIOS-LLERENA M. E. OŠLEJŠKOVÁ Hana ŠTĚRBA Jaroslav

Year of publication 2021
Type Article in Periodical
Magazine / Source Ceska a slovenska neurologie a neurochirurgie
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.csnn.eu/en/journals/czech-and-slovak-neurology-and-neurosurgery/2021-3-9/proteomics-of-cerebrospinal-fluid-in-pediatric-oncology-patients-127775?hl=cs
Doi http://dx.doi.org/10.48095/cccsnn2021245
Keywords proteomics; biomarkers; child; acute lymphoblastic leukemia; CNS neoplasmas
Description Major technological advances in the last two decades have led to the rise of proteomic analyses in various fields of medicine. In oncology, cerebrospinal fluid proteomics focuses on the detection of bio markers in primary CNS tumors and on the detection of CNS involvement secondarily or on the monitoring of neurological complications of treatment such as leukemias or lymphomas. Cytology may not be sensitive enough to detect such at-risk patients. In pediatric neuro-oncology, the dia gnosis and subsequent treatment of CNS tumors is currently based almost exclusively on histological and molecular bio logical examination of tumor tissue. However, in a large number of patients, resection or mere bio psy of the tumor is not possible due to the proximity of vital centers. In these cases, a reliable bio marker could help, providing more detailed information on dia gnosis, tumor classification, or risk assessment, or helping to identify potential treatment targets from better available bio logical material such as cerebrospinal fl uid. CNS relapse occurs in 3-8% of children with acute lymphoblastic leukemia. In addition, patients with confirmed CNS leukemia tend to have a worse treatment outcome. During treatment, pediatric patients also face numerous complications, one of the most serious being those affecting the CNS. The authors present an overview of the results of current studies dealing with cerebrospinal fluid proteomics in pediatric oncological patients.

You are running an old browser version. We recommend updating your browser to its latest version.